RELAPSED AND/OR REFRACTORY B-CELL LYMPHOMA Clinical Trials

17 clinical trials for RELAPSED AND/OR REFRACTORY B-CELL LYMPHOMA across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma — RECRUITING · PHASE1
• A PHASE II, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE OPTIMIZATION OF THE CYTOKINE RELEASE SYNDROME PROFILE FOR GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA — RECRUITING · PHASE2
• AN OPEN-LABEL, PHASE I/II STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOR ACTIVITY OF ENGLUMAFUSP ALFA (RO7227166, A CD19 TARGETED 4-1BB LIGAND) IN COMBINATION WITH OBINUTUZUMAB AND IN COMBINATION WITH GLOFITAMAB FOLLOWING A PRE-TREATMENT DOSE OF OBINUTUZUMAB ADMINISTERED IN PARTICIPANTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN¿S LYMPHOMA — RECRUITING · PHASE1
• RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EPCORITAMAB PLUS LENALIDOMIDE COMPARED TO RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN — RECRUITING · PHASE3
• EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING LISOCABTAGENE MARALEUCEL THAT IS NONCONFORMING TO COMMERCIAL RELEASE — RECRUITING
• A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO-501A, AN ANTI-CD-19 ALLOGENEIC CAR T CELL THERAPY, AND ALLO-647, AN ANTI-CD52 MONOCLONAL ANTIBODY, IN SUBJECTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (LBCL) — RECRUITING · PHASE1
• A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION TRIAL OF GEN3013 IN PATIENTS WITH RELAPSED, PROGRESSIVE OR REFRACTORY B-CELL LYMPHOMA — RECRUITING · PHASE1
• A MULTI-STAGE RANDOMIZED PHASE II STUDY OF NOVEL COMBINATION THERAPY IN THE TREATMENT OF RELAPSED AND REFRACTORY AGGRESSIVE B-CELL LYMPHOMA — RECRUITING · PHASE2
• The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma. — TERMINATED · PHASE1
• A PHASE 1/2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF KITE-363 OR KITE-753, AUTOLOGOUS ANTI-CD19/CD20 CAR T-CELL THERAPIES, IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY B-CELL LYMPHOMA — NOT_YET_RECRUITING · PHASE1
• A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF RONDECABTAGENE AUTOLEUCEL, AN AUTOLOGOUS, DUAL-TARGETING CD19/CD20 CAR T-CELL PRODUCT CANDIDATE, VERSUS INVESTIGATOR’S CHOICE OF CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE SECOND-LINE SETTING (PINACLE-H2H) — NOT_YET_RECRUITING · PHASE3
• A PHASE 2 NON-RANDOMIZED, OPEN-LABEL, MULTI-COHORT, MULTICENTER STUDY ASSESSING THE CLINICAL BENEFIT OF SAR444245 (THOR-707) WITH OR WITHOUT OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF ADULTS AND ADOLESCENTS WITH RELAPSED OR REFRACTORY B CELL LYMPHOMA (PEGASUS LYMPHOMA 205) — COMPLETED · PHASE2
• AN OPEN-LABEL, PHASE 2 TRIAL OF NANATINOSTAT IN COMBINATION WITH VALGANCICLOVIR IN PATIENTS WITH EPSTEIN-BARR VIRUS-POSITIVE (EBV+) RELAPSED/REFRACTORY LYMPHOMAS (NAVAL-1) — COMPLETED · PHASE2
• "A PHASE I/II TRIAL INVESTIGATING SAFETY AND EFFICACY OF AUTOLOGOUS TAC T CELLS TARGETING CD19 IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (TACTIC-19)." — NOT_YET_RECRUITING · PHASE1
• A PHASE IIIB, SINGLE ARM, OPEN LABEL, CANADIAN STUDY TO ASSESS THE SAFETY AND EFFICACY OF TISAGENLECLEUCEL FOR PATIENTS WITH LEUKAPHERESIS MATERIAL THAT DOES NOT MEET MANUFACTURING ACCEPTANCE SPECIFICATIONS AND/OR THE MANUFACTURED PRODUCT DOES NOT MEET APPROVED CANADIAN RELEASE SPECIFICATIONS — COMPLETED · PHASE3
• "A MULTICENTER, OPEN-LABEL, EXPANDED ACCESS STUDY OF AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF SUBJECTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA." — NOT_YET_RECRUITING
• PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF THE ANTIBODY-DRUG CONJUGATE TRPH-222 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY B-CELL LYMPHOMA — COMPLETED · PHASE1

Refine this search